Dermatoosteolysis, Kirghizian type

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1657OMIM:221810Q82.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Dermatoosteolysis, Kirghizian type, is an extremely rare inherited condition that affects both the skin and bones. The name comes from the combination of 'dermato' (skin) and 'osteolysis' (bone destruction or dissolving). It was first described in families from the Kirghiz (Kyrgyz) population of Central Asia. In this condition, affected individuals develop skin abnormalities, including thickening, scarring, or breakdown of the skin, along with progressive destruction of bone tissue, particularly in the hands and feet. The bone changes can lead to shortening or loss of fingers and toes over time. Skin findings may include nodules, ulcers, or areas of abnormal scarring. The condition typically begins in childhood and can progressively worsen. Because this disease is so rare, with only a handful of cases reported in the medical literature, the full range of symptoms and the underlying genetic cause are not yet completely understood. There is currently no cure for this condition. Treatment focuses on managing symptoms, protecting the skin, and addressing bone complications. Patients benefit from a team of specialists including dermatologists, orthopedic surgeons, and geneticists who work together to provide the best possible care and quality of life.

Key symptoms:

Progressive destruction of bones in the hands and feetShortening or loss of fingers and toesSkin thickening or hardeningSkin ulcers or open soresScarring of the skinSkin nodules or lumpsJoint stiffness or deformityPain in the hands and feetFragile or easily damaged skinNail abnormalities

Clinical phenotype terms (21)— hover any for plain English
Abnormal diaphysis morphologyHP:0000940Dystrophic toenailHP:0001810Dystrophic fingernailsHP:0008391
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Dermatoosteolysis, Kirghizian type.

View clinical trials →

No actively recruiting trials found for Dermatoosteolysis, Kirghizian type at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Dermatoosteolysis, Kirghizian type community →

No specialists are currently listed for Dermatoosteolysis, Kirghizian type.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Dermatoosteolysis, Kirghizian type.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Dermatoosteolysis, Kirghizian typeForum →

No community posts yet. Be the first to share your experience with Dermatoosteolysis, Kirghizian type.

Start the conversation →

Latest news about Dermatoosteolysis, Kirghizian type

No recent news articles for Dermatoosteolysis, Kirghizian type.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How can we monitor the progression of bone changes in my child's hands and feet?,What is the best approach to managing skin wounds and preventing infection?,Are there any genetic tests that could help confirm the diagnosis or identify the specific gene involved?,What physical or occupational therapy options are available to help maintain function?,Should other family members be tested or evaluated?,Are there any clinical trials or research studies we could participate in?,What signs should prompt us to seek emergency care?

Common questions about Dermatoosteolysis, Kirghizian type

What is Dermatoosteolysis, Kirghizian type?

Dermatoosteolysis, Kirghizian type, is an extremely rare inherited condition that affects both the skin and bones. The name comes from the combination of 'dermato' (skin) and 'osteolysis' (bone destruction or dissolving). It was first described in families from the Kirghiz (Kyrgyz) population of Central Asia. In this condition, affected individuals develop skin abnormalities, including thickening, scarring, or breakdown of the skin, along with progressive destruction of bone tissue, particularly in the hands and feet. The bone changes can lead to shortening or loss of fingers and toes over tim

How is Dermatoosteolysis, Kirghizian type inherited?

Dermatoosteolysis, Kirghizian type follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Dermatoosteolysis, Kirghizian type typically begin?

Typical onset of Dermatoosteolysis, Kirghizian type is childhood. Age of onset can vary across affected individuals.